Concepedia

David Luo

DL

14

Publications

1.7K

Citations

13

H-Index

2001

Active since

Affiliations

Ignyta (United States)(Current)

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Memorial Sloan Kettering Cancer Center

Fondazione IRCCS Istituto Nazionale dei Tumori

Massachusetts General Hospital

David Luo is an author at Ignyta (United States) specializing in medicine, oncology, and pathology.

Top concepts

Publications per year

2001–2021

14

Publications

14

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 795 citations · Full text

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Elena Ardini, Roberta Bosotti et al. · JNCI Journal of the National Cancer Institute · 2015 · 245 citations · Full text

, , +15

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Anna F. Farago, Long P. Le, Zongli Zheng et al. · Journal of Thoracic Oncology · 2015 · 224 citations · Full text

, , +5

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Alessio Amatu, Alessio Somaschini, Giulio Cerea et al. · British Journal of Cancer · 2015 · 84 citations · Full text

Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells

Rosângela Salerno-Gonçalves, David Luo, Stéphanie Fresnay et al. · Frontiers in Immunology · 2017 · 62 citations · Full text

Rows per page

1–5 of 14